Welcome!

News Feed Item

Prosonix' Marketing Authorisation Application for PSX1001 - a Generic Version of GlaxoSmithKline's Flixotide® Evohaler® - Under Assessment in EU

QXFORD, England, September 2, 2014 /PRNewswire/ --


Triggers milestone payment from Mylan 

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being assessed under the Decentralised Procedure (DCP), in which the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) is the Reference Member State. Prosonix has submitted the primary MAA under the DCP and a simultaneous duplicate MAA on behalf of Mylan Inc.

The MAA submission for PSX1001 leverages the EU regulatory guideline CPMP/EWP/4151/00 Rev. 1 that potentially allows the approval of generic inhaled products on the basis of in vitro only demonstration of therapeutic equivalence of the candidate to the reference product.  

The achievement of this milestone has triggered a payment from Mylan under the terms of the licensing agreement for Prosonix' inhaled respiratory products, PSX1001 and PSX1050, announced in April 2014.

PSX1001 and PSX1050 are the first products to emerge from Prosonix's innovative and proprietary particle engineering platform, and are being developed as generic versions to GSK's pressurised metered dose inhalers (pMDI) Flixotide® (EU and ROW) and Flovent® (US), respectively. Flixotide and Flovent contain the active ingredient fluticasone propionate, a potent inhaled corticosteroid, and are indicated for the treatment of asthma. According to IMS Health, Flixotide and Flovent had global brand sales of approximately $1.3 billion in 2013.

David Hipkiss, CEO and Co-founder of Prosonix, said: "The achievement of this key milestone is a landmark event for Prosonix. Our MAA for PSX1001 is the first of our product pipeline to be reviewed under the EU regulatory guidelines that allow the potential approval of generic inhaled products based on in vitro data alone. We are excited to be able to use this regulatory approach to deliver our strategy, consistent with the new Global Initiative for Asthma (GINA) management and prescribing guidelines which we believe are set to dominate the reimbursement and payer agenda for the foreseeable future."

Under the terms of the global licensing agreement signed by Prosonix and Mylan, Prosonix are responsible for filing PSX1001 in the EU and retain marketing rights in certain territories. Mylan has marketing rights for PSX1001 and PSX1050 in the U.S., Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States. All other terms of the agreement remain confidential.

About Asthma 

Asthma is a chronic disease of the air passages of the lungs causing inflammation and a narrowing of the airways that reduces the flow of air into and out of the lungs. According to the World Health Organization approximately 235 million people worldwide suffer from asthma currently with a further 100 million patients forecast by 2025. It is a common disease among children. The strongest risk factors for developing asthma are inhaled substances and particles that may provoke allergic reactions or irritate the airways. Medication can control asthma and current standard of care (SoC) includes inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABAs), alone or in combination. Appropriate management of asthma can enable people to enjoy a good quality of life.

About Prosonix          

http://www.prosonix.co.uk 

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design. Its investors include Entrepreneurs Fund, Gilde Healthcare, Gimv, Quest for Growth, Solon Ventures and Ventech.

Prosonix' proprietary particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products.

Prosonix' pipeline focuses on near- and long-term opportunities, and is further complemented by a select number of partnered respiratory programmes.  The in-house pipeline includes:

  • PSX1001 and PSX1050, generic versions of GlaxoSmithKline's Flixotide®/Flovent® monotherapy containing fluticasone propionate (FP), a potent ICS, in development for asthma in pMDI; partnered with Mylan in certain territories,
  • PSX2005, a generic version of GSK's Seretide® combination product consisting of FP and salmeterol xinafoate (SX) a long-acting beta agonist (LABA) in development for asthma and COPD in pMDI,
  • PSX1002, a drug-only proprietary formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), currently in Phase 2 clinical studies for COPD in pMDI, and
  • PSX MCP™ Series, novel dual and triple fixed dose combination products (ICS/LABA, ICS/LAMA, LABA/LAMA, and ICS/LABA/LAMA) designed specifically for respiratory diseases and based on the unique features and benefits of Prosonix proprietary Multi-component Particles™. MCPs™ do not require additional functional excipients, adjuvants, or co-suspension agents for optimal formulation performance from pMDI or Dry Powder Inhalers (DPI).

Additional partnered respiratory programmes include:

  • PX1439, a generic version of GSK's Serevent® monotherapy (SX, LABA) in pMDI
  • PX1442, a generic version of Boehringer Ingelheim's Spiriva® (tiotropium bromide, LAMA) in a capsule-based DPI.

Global Initiative for Asthma (GINA) Guidelines - Updated July 2014 

Evohaler® Flixotide®, Flovent®, Seretide® and Serevent® are trademarks of the GlaxoSmithKline group of companies. 

Spiriva® is a trademark of Boehringer Ingelheim. 

Contacts:
David Hipkiss, CEO
+44-(0)1865-784-250
[email protected]

Mark Swallow, Sita Shah, David Dible
Citigate Dewe Rogerson
+44-(0)207-638 9571
[email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
In his session at @ThingsExpo, Kausik Sridharabalan, founder and CTO of Pulzze Systems, Inc., will focus on key challenges in building an Internet of Things solution infrastructure. He will shed light on efficient ways of defining interactions within IoT solutions, leading to cost and time reduction. He will also introduce ways to handle data and how one can develop IoT solutions that are lean, flexible and configurable, thus making IoT infrastructure agile and scalable.
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software sec...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera M...
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of (at least) three separate application components: the software embedded in the device, the back-end service, and the mobile application for the end user’s controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/target –...